Iovance Presents Five-Year Amtagvi Data at ASCO for Advanced Melanoma
A five-year overall survival rate of 19.7% and a median overall survival of 13.9 months were reported in 153 patients with advanced melanoma who had previously received anti-PD-1 and targeted treatments...